PYC Therapeutics Limited (ASX:PYC)
Australia · Delayed Price · Currency is AUD 2.250
-0.010 (-0.44%)
Aug 28, 2026, 4:10 PM AEST
PYC Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Other Revenue | 39.68 | 23.49 | 22.06 | 15.81 | 16.04 |
| 39.68 | 23.49 | 22.06 | 15.81 | 16.04 | |
Revenue Growth | 68.88% | 6.50% | 39.56% | -1.47% | 421.83% |
Gross Profit | 39.68 | 23.49 | 22.06 | 15.81 | 16.04 |
Selling, General & Admin | 9.42 | 7.07 | 4.51 | 4.09 | 6.3 |
Research & Development | 73.98 | 70.05 | 56.41 | 35.15 | 24.03 |
Operating Expenses | 83.4 | 77.12 | 60.92 | 39.24 | 30.33 |
Operating Income | -43.73 | -53.63 | -38.86 | -23.43 | -14.29 |
Interest Expense | -0.04 | -0.06 | -0.05 | -0.03 | -0.03 |
Interest & Investment Income | - | 2.68 | 0.8 | 0.08 | 0.02 |
EBT Excluding Unusual Items | -43.77 | -51.01 | -38.11 | -23.38 | -14.29 |
Gain (Loss) on Sale of Assets | - | - | - | 0.02 | - |
Pretax Income | -43.77 | -51.01 | -38.11 | -23.36 | -14.29 |
Earnings From Continuing Operations | -43.77 | -51.01 | -38.11 | -23.36 | -14.29 |
Minority Interest in Earnings | 0.43 | 0.71 | 0.39 | 0.57 | 0.43 |
Net Income | -43.34 | -50.3 | -37.73 | -22.79 | -13.86 |
Net Income to Common | -43.34 | -50.3 | -37.73 | -22.79 | -13.86 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 733 | 501 | 394 | 321 | 318 |
Shares Outstanding (Diluted) | 733 | 501 | 394 | 321 | 318 |
Shares Change | 46.52% | 27.16% | 22.59% | 0.93% | 2.89% |
EPS (Basic) | -0.06 | -0.10 | -0.10 | -0.07 | -0.04 |
EPS (Diluted) | -0.06 | -0.10 | -0.10 | -0.07 | -0.04 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -45.05 | -52.54 | -38.9 | -24.91 | -22.17 |
Free Cash Flow Per Share | -0.06 | -0.10 | -0.10 | -0.08 | -0.07 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -110.21% | -228.26% | -176.15% | -148.24% | -89.05% |
Profit Margin | -109.23% | -214.11% | -171.02% | -144.18% | -86.41% |
Free Cash Flow Margin | -113.54% | -223.61% | -176.32% | -157.61% | -138.19% |
EBITDA | -42.52 | -52.88 | -38.12 | -22.8 | -13.69 |
EBITDA Margin | -107.17% | -225.06% | -172.80% | -144.25% | -85.31% |
D&A For EBITDA | 1.2 | 0.75 | 0.74 | 0.63 | 0.6 |
EBIT | -43.73 | -53.63 | -38.86 | -23.43 | -14.29 |
EBIT Margin | -110.21% | -228.26% | -176.15% | -148.24% | -89.05% |
Revenue as Reported | 39.68 | 26.17 | 22.86 | 15.91 | 16.07 |